Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 08 01 2018
revised: 27 06 2018
accepted: 01 08 2018
pubmed: 19 9 2018
medline: 16 4 2019
entrez: 19 9 2018
Statut: ppublish

Résumé

Metabolic alterations are increasingly recognized as important novel anti-cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3

Identifiants

pubmed: 30226266
doi: 10.1002/ijc.31868
pmc: PMC6261695
mid: NIHMS993076
doi:

Substances chimiques

Enzyme Inhibitors 0
PFK158 0
Pyridines 0
Quinolines 0
Carboplatin BG3F62OND5
PFKFB3 protein, human EC 2.7.1.105
Phosphofructokinase-2 EC 2.7.1.105
Paclitaxel P88XT4IS4D

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-189

Subventions

Organisme : NCI NIH HHS
ID : P50 CA136393
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA106954
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Am J Clin Oncol. 2011 Dec;34(6):628-35
pubmed: 20805739
Trends Endocrinol Metab. 2011 Jun;22(6):234-40
pubmed: 21419642
Sci Rep. 2017 Feb 07;7:41977
pubmed: 28169314
Cell Death Discov. 2016 Aug 22;2:16061
pubmed: 27625792
Cell. 2013 Aug 1;154(3):651-63
pubmed: 23911327
J Biol Chem. 2010 Feb 5;285(6):3713-21
pubmed: 19948719
Cancer Res. 2009 Jun 1;69(11):4843-50
pubmed: 19487294
Cancer Metab. 2014 Jan 23;2(1):2
pubmed: 24451478
Nature. 2009 Apr 30;458(7242):1131-5
pubmed: 19339967
Nat Rev Cancer. 2003 Jul;3(7):502-16
pubmed: 12835670
Adv Enzyme Regul. 1993;33:97-110
pubmed: 8395137
Autophagy. 2009 Oct;5(7):1018-25
pubmed: 19652534
Curr Cancer Drug Targets. 2011 Feb;11(2):226-35
pubmed: 21158717
Clin Cancer Res. 2005 Aug 15;11(16):5784-92
pubmed: 16115917
Trends Biochem Sci. 2001 Jan;26(1):30-5
pubmed: 11165514
Oncotarget. 2015 Oct 20;6(32):33705-19
pubmed: 26378042
Biochem J. 2013 Jun 15;452(3):531-43
pubmed: 23548149
J Biol Chem. 2002 Aug 23;277(34):30778-83
pubmed: 12065600
Cell Rep. 2017 Apr 4;19(1):1-9
pubmed: 28380348
Oncotarget. 2015 Nov 3;6(34):36354-69
pubmed: 26497553
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Mol Cell Biochem. 2005 Dec;280(1-2):1-8
pubmed: 16511951
Cancer Metab. 2014 Aug 18;2:13
pubmed: 25225614
Biochim Biophys Acta. 2014 Dec;1841(12):1661-71
pubmed: 25450448
PLoS One. 2012;7(3):e34277
pubmed: 22479585
Magn Reson Med. 2012 Aug;68(2):369-77
pubmed: 22161549
Mol Cancer Ther. 2011 Mar;10(3):427-36
pubmed: 21282354
Stem Cells. 2015 Apr;33(4):1366-70
pubmed: 25586989
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Metabolomics. 2013 Jun;9(3):722-729
pubmed: 23678346
Mol Cancer. 2010 Sep 13;9:239
pubmed: 20836852
Prog Lipid Res. 2013 Oct;52(4):585-9
pubmed: 24001676
Mol Cancer Ther. 2008 Jan;7(1):110-20
pubmed: 18202014
Cell Death Differ. 2013 Jan;20(1):3-11
pubmed: 22595754
Biochim Biophys Acta. 2008 Aug;1783(8):1544-50
pubmed: 18406359
Cell Death Dis. 2014 Jul 17;5:e1337
pubmed: 25032860
Nat Cell Biol. 2015 Jun;17(6):759-70
pubmed: 25961502
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Int J Mol Sci. 2016 Aug 31;17(9):
pubmed: 27589734
Cell. 2010 Jan 8;140(1):49-61
pubmed: 20079333
Mol Cancer Ther. 2013 Aug;12(8):1461-70
pubmed: 23674815
FEBS J. 2016 Aug;283(15):2767-78
pubmed: 26881388
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Science. 2004 Nov 19;306(5700):1383-6
pubmed: 15550674

Auteurs

Susmita Mondal (S)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.
Department of Microbiology, Sammilani Mahavidyalaya, Kolkata, India.

Debarshi Roy (D)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Sayantani Sarkar Bhattacharya (S)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Ling Jin (L)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Deokbeom Jung (D)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Song Zhang (S)

Division of Cardiovascular disease, Department of Medicine, Mayo Clinic, Rochester, MN.

Eleftheria Kalogera (E)

Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN.

Julie Staub (J)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Yaxian Wang (Y)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Wen Xuyang (W)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Ashwani Khurana (A)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Jeremey Chien (J)

Division of Molecular Medicine, University of New Mexico School of Medicine, Albuquerque, NM.

Sucheta Telang (S)

Department of Medicine, University of Louisville, Louisville, KY.

Jason Chesney (J)

Department of Medicine, University of Louisville, Louisville, KY.

Gilles Tapolsky (G)

Advanced Cancer Therapeutics, Louisville, KY.

Dzeja Petras (D)

Division of Cardiovascular disease, Department of Medicine, Mayo Clinic, Rochester, MN.

Viji Shridhar (V)

Department of Experimental Pathology, Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH